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EPIDEMIOLOGY AND PREVENTION
HighMedicationAdherenceDuring Periconception Periods
Among HIV-1–Uninfected Women Participating in
a Clinical Trial of Antiretroviral Pre-exposure Prophylaxis
Lynn T. Matthews, MD, MPH,*† Renee Heffron, PhD,‡ Nelly R. Mugo, MbChB, MMed, MPH,‡§
Craig R. Cohen, MD, MPH,k Craig W. Hendrix, MD,¶ Connie Celum, MD, MPH,‡#**
David R. Bangsberg, MD, MPH,*† and Jared M. Baeten, MD, PhD,‡#** for the Partners PrEP Study Team
Introduction: Pre-exposure prophylaxis (PrEP) may be an impor-
tant safer conception strategy for HIV-1–uninfected women with
HIV-1–infected partners. Understanding medication adherence in
this population may inform whether PrEP is a feasible safer concep-
tion strategy.
Methods: We evaluated predictors of pregnancy and adherence to
study medication among HIV-1–uninfected women enrolled in a ran-
domized placebo-controlled trial of PrEP among African HIV-1–
serodiscordant couples. Participants were counseled on HIV-1 risk
reduction, contraception, and adherence and tested for pregnancy at
monthly study visits. Pill counts of dispensed drug were performed
and, at a subset of visits, plasma was collected to measure active
drug concentration.
Results: Among 1785 women, pregnancy incidence was 10.2 per
100 person-years. Younger age, not using contraception, having an
additional sexual partner, and reporting unprotected sex were
associated with increased likelihood of pregnancy. Monthly clinic
pill counts estimated that women experiencing pregnancy took 97%
of prescribed doses overall, with at least 80% pill adherence for 98%
of study months, and no difference in adherence in the periconcep-
tion period compared with previous periods (P = 0.98). Tenofovir
was detected in plasma at 71% of visits where pregnancy was dis-
covered. By multiple measures, adherence was similar for women
experiencing and not experiencing pregnancy (P $ 0.1).
Conclusions: In this clinical trial of PrEP, pregnancy incidence
was 10% per year despite excellent access to effective contra-
ception. Women experiencing pregnancy had high medication
adherence, suggesting that PrEP may be an acceptable and
feasible safer conception strategy for HIV-1–uninfected women
with HIV-1–serodiscordant partners.
Key Words: pregnancy, HIV-1 prevention, pre-exposure prophy-
laxis, adherence, safer conception, serodiscordant couples,
sub-Saharan Africa
(J Acquir Immune Defic Syndr 2014;67:91–97)
INTRODUCTION
For women in sub-Saharan Africa, having biologic
children is important to secure a relationship, prove suitability
as a spouse, maintain marriage, expand family lineage, and
demonstrate health.1,2 For women at risk for HIV-1 acquisi-
tion, including women in HIV-1–serodiscordant relationships
(where 1 partner is HIV-1 infected and the other is not),
pregnancy desires are common3–6 but conception attempts
risk sexual HIV-1 acquisition. HIV-1–uninfected women
who attempt to conceive with an HIV-1–infected partner or
a partner of unknown HIV-1 status need safe, feasible, and
effective strategies to reduce HIV-1 acquisition risk.
Antiretroviral pre-exposure prophylaxis (PrEP) could
be a key component of safer conception strategies for women
in HIV-1–serodiscordant couples, particularly when the
infected partner is not eligible, willing, or able to take anti-
retroviral treatment (ART).7–13 Oral tenofovir (TDF) and co-
formulated emtricitabine (FTC)/TDF, the antiretrovirals
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studied in PrEP efficacy trials conducted to date, have an
excellent safety profile among pregnant and breastfeeding
women14,15; however, clinical trials of PrEP, like most trials
of novel pharmacologic therapies, encouraged delaying preg-
nancy and withheld study drug during pregnancy to minimize
fetal exposure. Nevertheless, pregnancy incidence has been
high among HIV-1–uninfected women in trials of biomedical
HIV-1 prevention interventions, including trials of PrEP.16–20
Given high pregnancy incidence and associated risks of
HIV-1 acquisition, understanding correlates of pregnancy
among women in HIV-1 prevention trials may inform safer
conception programs.
PrEP effectiveness is highly dependent on adher-
ence,7,8,21–23 and PrEP efficacy trials offer an early opportu-
nity to identify populations for whom medication adherence
may be challenging. Women who desire children might
adhere to prevention strategies to protect a potential child
from acquiring HIV-14,24–26 or, alternatively, may not adhere
out of fear of side effects, including effects on the fetus.
Understanding PrEP adherence in the context of conception
is important given the potential of periconception PrEP as an
HIV-1 risk-reduction strategy.10–12,27
We evaluated predictors of pregnancy and adherence
to study medication before and during periconception
among African HIV-1–uninfected women in serodiscordant
partnerships enrolled in a randomized placebo-controlled
trial of oral PrEP.
METHODS
Study Population and Procedures
The Partners PrEP Study was a phase III, randomized,
double-blind, placebo-controlled, 3-arm clinical trial of daily
oral TDF and FTC/TDF PrEP or placebo provided to HIV-1–
uninfected members of HIV-1–serodiscordant couples.
Beginning in July 2008, 4747 HIV-1–serodiscordant couples
were enrolled and followed at 9 research sites in Kenya and
Uganda. Eligible couples were sexually active and planned to
remain in the relationship for the duration of the study. HIV-
1–uninfected participants had normal renal function and were
not infected with Hepatitis B virus. HIV-1–uninfected women
were neither pregnant nor immediately planning pregnancy at
the time of enrollment, counseled to delay pregnancy until the
end of the study, and offered contraception, provided at no
cost on-site. HIV-1–infected partners were not receiving and
did not meet Kenyan or Ugandan guidelines for initiation of
ART at enrollment and were monitored and actively referred
for ART initiation if they became eligible during study
follow-up. At each study visit, couples received a package
of HIV-1 prevention services, including risk-reduction coun-
seling, couples counseling, and condoms.8,28
At monthly follow-up visits for up to 36 months, HIV-
1–uninfected partners underwent rapid HIV-1 testing, dispen-
sation of study medication, and adherence counseling. For
HIV-1–uninfected women, monthly visits included pregnancy
testing with urine b-HCG and contraceptive counseling and
provision; pregnant women were referred to local antenatal
clinics, and study drug was held during pregnancy and
breastfeeding. Testing for sexually transmitted infections
(Neisseria gonorrhoeae, Chlamydia trachomatis, and
Trichomonas vaginalis) was conducted at baseline and
annually. Interviewer-administered questionnaires captured
demographic, partnership characteristics, sexual behavior,
contraceptive use, and medical history data.
In July 2011, the trial’s independent Data and Safety
Monitoring Board recommended discontinuation of the trial
placebo arm and public report of the results due to demon-
stration of PrEP efficacy for HIV-1 protection.8
The study protocol was reviewed by human subjects
committees at the University of Washington and all study
sites. Participants provided written informed consent.
Statistical Methods
This analysis includes data collected up to July 2011,
when primary efficacy results were disseminated and the
placebo arm was discontinued, and is limited to 1785 couples
with HIV-1–uninfected female partners. Follow-up time from
women who seroconverted to HIV-1 was censored at the time
of seroconversion.
Pregnancy Incidence and Correlates
Pregnancy incidence was calculated as the number of
new pregnancies divided by the total person-years of follow-
up (excluding pregnant follow-up time). Baseline and time-
dependent factors associated with incident pregnancy were
examined using an Andersen–Gill29 extension to the Cox pro-
portional hazards model to allow for multiple pregnancies per
woman. Adjusted models included all factors associated with
incident pregnancy in univariate analysis at P , 0.05.
Study Medication Adherence Among Women
With and Without Pregnancy
We used several approaches to assess adherence to
study medication. Pill count adherence was calculated from
monthly clinic counts of dispensed and returned study pills,
based on date of study dispensation and days since last visit.
Missed visits were assigned an adherence value of zero
because a missed visit corresponded with no pills dispensed.
Previous work conducted in a subset of Partner PrEP Study
participants showed high correlation between clinic-based pill
counts, unannounced home pill counts, and electronic
monitoring of pill bottle opening.30
We used log-binomial regression with generalized
estimating equations to compare the relative risk of adhering
to at least 80% of study drug doses among HIV-1–uninfected
women who experienced pregnancy compared with women
who did not experience pregnancy.31 High adherence was
defined as taking at least 80% of doses based on biologic
plausibility,32 prior definitions of low and high adherence to
antiretroviral PrEP,7 and prior adherence data from this
study.30 A priori specified covariates included age, unpro-
tected sex, sex with an additional partner, use of an effective
contraceptive method, and time in the study.
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To examine the relationship between periconception
periods of follow-up and adherence to study drug restricted to
women who became pregnant (thus removing differences
between women who did and did not experience pregnancy),
we evaluated adherence during the periconception period,
defined as the 3 months before the visit at which the first
pregnancy was discovered, compared with follow-up before
the periconception period. To minimize confounding by
enrollment characteristics that could be associated with both
adherence and becoming pregnant, we used conditional
logistic regression33 with adjustment for time-dependent con-
founders (any unprotected sex, sex with an additional partner,
use of an effective contraceptive method, and time in the
study), selected a priori based on factors with strong associ-
ations with pregnancy.
Finally, for women randomized to the trial’s active arms
(TDF or FTC/TDF), stored plasma from selected study visits
was tested for tenofovir drug concentrations, using methods
previously described (assay limit of quantitation = 0.3 ng/mL).8
For the present analysis, we tested samples from the visit at
which pregnancy was first discovered among women who
became pregnant and had a sample available from this study
visit. Detection of tenofovir was compared between these sam-
ples and specimens from a randomly selected cohort of women
who did not become pregnant; samples from the random
cohort were tested from across the study follow-up (months
1, 3, 6, 12, 18, 24, and 36, as available depending on the
length of follow-up). For this analysis, a priori specified
covariates included age, any unprotected sex, sex with an
additional partner, use of an effective contraceptive method,
and time in the study. This analysis was conducted in
R version 2.12.2 using the Lumley survey package (version
3.26 http://faculty.washington.edu/tlumley/survey/).34 All
other analyses were conducted using SAS version 9.3
(SAS Institute, Cary, NC).
RESULTS
Participant Characteristics
The median age of the 1785 HIV-1–uninfected women
included in this analysis was 33 years [interquartile range
(IQR), 28–38], median partnership duration was 12 years
(IQR, 6–19), and median number of children was 4 (2–5)
with 5% of women reporting no children (Table 1).
Twenty-three percent of women reported sex without con-
doms in the month before enrollment and 53% were not using
effective contraception.
Pregnancy Incidence and Predictors
During 2827.5 person-years of follow-up, 267 women
had 288 pregnancies for an incidence of 10.2 pregnancies
per 100 person-years of follow-up [95% confidence interval
(CI): 9.1 to 11.3]. Of the 267 women who became pregnant,
247 had 1 pregnancy and 20 had 2 pregnancies. Pregnancies
occurred steadily throughout the follow-up period (data
not shown). In multivariate analysis, multiple factors
were independently associated with increased likelihood of
pregnancy (Table 1): unprotected sex with the study partner
[adjusted hazard ratio (aHR), 3.04; 95% CI: 2.28 to 4.05],
having an additional sexual partner during follow-up (aHR,
2.57; 95% CI: 1.44 to 4.56), younger age (aHR, 11.12, 95%
CI: 5.23 to 23.63, for age 18–29 and aHR 5.78, 95% CI:
2.86 to 11.70, for age 30–39, each compared with age $40
years), and not using effective contraception (aHR 3.89,
95% CI: 2.93 to 5.16). Effective contraceptive use was re-
ported at 57.6% of follow-up visits, a proportion that was
relatively consistent throughout follow-up (ranging from
54.1% to 62.2%).
Pregnancy and Adherence to Study Drug
Clinic-based pill count adherence was high, with 97.0%
(SD, 6.9) of dispensed pills taken by women who experienced
a pregnancy and 97.9% (SD, 6.0) taken by women without
pregnancies. High adherence (defined as $80% of dispensed
pills taken) was present at 97.7% of visits among women
who became pregnant, which was not statistically different
than among women who did not become pregnant, for
whom $80% adherence was present for 98.7% of visits
[adjusted relative risk (aRR), 0.99; 95% CI: 0.99 to 1.0; Table 2].
To discern whether adherence differed relative to the
time of pregnancy, we conducted an analysis of adherence
among the subset of women who became pregnant. In these
women, the likelihood of adhering to at least 80% of pills
dispensed during the 3-month periconception period was
similar to other time points before pregnancy in unadjusted
analysis (odds ratio, 0.88; 95% CI: 0.50 to 1.55) and after
adjustment for effective contraceptive use, unprotected sex,
additional partners, and time in study (adjusted odds ratio =
1.01; 95% CI: 0.50 to 2.04; P = 0.98) (Fig. 1 and Table 2).
We also evaluated tenofovir concentrations among
pregnant and nonpregnant follow-up periods. Tenofovir
plasma concentrations were available from 76 women who
became pregnant at the visit when their pregnancy was first
discovered (77 specimens, with 1 woman having 2 pregnan-
cies) and 103 women who did not become pregnant (329
specimens across their follow-up, with a median of 4 samples
per woman). Tenofovir was detectable (consistent with
dosing in the previous week) in 71% (55/77) of specimens
from women who became pregnant and 81% (252/313) of
specimens from women not experiencing pregnancy (aHR,
0.81; 95% CI: 0.43 to 1.52). There was also no statistically
significant difference when a higher concentration cutoff was
used ($40 ng/mL of tenofovir, suggesting steady-state dos-
ing, data not shown).
DISCUSSION
As in many clinical trials of biomedical interventions,
women were eligible for enrollment into the Partners PrEP
Study if they were not pregnant and reported no plans for
pregnancy. The trial protocol included counseling to avoid
pregnancy, contraceptive counseling, and provision of free
contraception, without a requirement for contraception. In
these circumstances, just over half of women used effective
contraception, and pregnancy incidence was 10% per year
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among HIV-1–uninfected women with HIV-1–infected part-
ners. By multiple measures, adherence to study drug
(blinded PrEP or placebo) was high among women experi-
encing pregnancy.
Medication adherence has been low in some studies of
PrEP for women.22,23 However, in the Partners PrEP Study,
adherence was high, by multiple measures.8,30 In the present
analysis, we found that women with and without pregnancies
had high adherence to study drug, as measured both by pill
counts and detection of tenofovir in plasma. Because women
in PrEP trials have been encouraged to delay pregnancy and
counseled about unclear safety data for tenofovir use in early
pregnancy, we explored whether women with pregnancy were
less likely to take study drug during the periconception
period, but found no difference. These data suggest that
women were willing to use PrEP around the time of concep-
tion, even in the absence of data regarding the safety and
efficacy of PrEP for HIV-1 prevention.
In contrast to these results, among women with
pregnancy in CAPRISA 004, a median of 50% of sex acts
TABLE 1. Participant Characteristics and Associations With Incident Pregnancy
Prevalence/Frequency at
Baseline Factors Associated With Incident Pregnancy








Active PrEP arm (ref. placebo) 1164 (65) 1.00 (0.77 to 1.29) 1.0
Age (yrs) 33 (28–38) — — — —
18–29 586 (33) 13.17 (6.73 to 25.79) ,0.001 11.12 (5.23 to 23.63) ,0.001
30–39 832 (47) 6.08 (3.09 to 11.96) ,0.001 5.78 (2.86 to 11.70) ,0.001
$40 367 (21) Reference — Reference —
Partnership duration (yrs) 12 (6–19) 0.93 (0.91 to 0.94) ,0.001 0.98 (0.96 to 1.01) 0.1
Number of children 4 (2–5) — — — —
0 81 (5) Reference — — —
1 child 183 (10) 1.73 (0.89 to 3.35) 0.1 — —
2–3 children 553 (31) 1.27 (0.68 to 2.40) 0.5 — —
.4 children 968 (54) 0.83 (0.44 to 1.55) 0.6 — —
Any income (ref. none) 1242 (69) 0.83 (0.65 to 1.08) 0.2 — —
Sexual behavior
Coital frequency* 4 (2–8) 1.02 (1.00 to 1.05) 0.05
Any unprotected sex with study partner (ref.
none)*
406 (23) 2.93 (2.24 to 3.83) ,0.001 3.04 (2.28 to 4.05) ,0.001
Any sex with additional partner(s) (ref. none)* 8 (0.5) 3.28 (1.96 to 5.49) ,0.001 2.57 (1.44 to 4.56) 0.001
Clinical characteristics
BMI (kg/m2) 23 (21–26) — — — —
,18.5 100 (6) 1.21 (0.77 to 1.90) 0.4 — —
18.5–24.9 1160 (65) Reference — — —
25–29.9 389 (22) 0.95 (0.70 to 1.29) 0.7 — —
$30 136 (8) 0.75 (0.46 to 1.22) 0.2 — —
No effective contraception† (ref. any
contraception)*
948 (53) 2.80 (2.16 to 3.63) ,0.001 3.89 (2.93 to 5.16) ,0.001
Sexually transmitted infection‡ 144 (8) 1.53 (1.02 to 2.28) 0.04 1.35 (0.90 to 2.02) 0.2
Male partner characteristics
Age of male partner (yrs) 39 (33–44) — — — —
18–29 182 (10) 3.64 (2.53 to 5.25) ,0.001 1.25 (0.80 to 1.93) 0.3
30–39 788 (44) 2.48 (1.86 to 3.31) ,0.001 1.35 (0.98 to 1.86) 0.06
$40 815 (46) Reference — — —
Male partner ART use* — 0.56 (0.31 to 1.01) 0.06 — —
Male partner CD4 cell count (cells/mm3)* 457 (354–596) — — — —
,250 0 (0) 0.75 (0.53 to 1.06) 0.1 — —
250–349 420 (24) 0.90 (0.69 to 1.18) 0.5 — —
350–500 649 (36) 1.02 (0.62 to 1.67) 0.9 — —
.500 716 (40) Reference — — —
*Analyzed as a time-dependent factor in longitudinal analysis of factors associated with incident pregnancy. N (%) or median (IQR) are from the time of enrollment.
†Effective contraception defined as use of oral, injectable, implant, or intrauterine device; women having undergone a hysterectomy were excluded from the analysis.
‡Sexually transmitted infections including Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis.
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were protected according to the dosing schedule of 2 gel
applications per sex act. Women with pregnancy were about
half as likely to adhere to at least 80% of study gel doses
compared with women without pregnancy.35 Several differ-
ences in study populations may explain these differences. The
CAPRISA 004 study required participants to start contracep-
tion at trial entry—use was 100% at baseline and 97% at
18 months36; thus, women with pregnancies in that study
may have been less likely to adhere to study gel because
pregnancies also likely reflected nonadherence to contracep-
tion. In addition, CAPRISA 004 enrolled individual younger
women (median age 22) at high risk for HIV-1 acquisition,
whereas the Partners PrEP Study enrolled older women
(median age, 33) in known HIV-1–serodiscordant couples.
TABLE 2. Adherence to Study Medication (PrEP/Placebo), by Multiple Measures
% of Visit Months With ‡80% Adherence
RR of ‡80% Adherence
(95% CI); P
Adjusted RR of ‡80%
Adherence (95% CI); P
Clinic-based pill count adherence, women experiencing
pregnancy vs. women not experiencing pregnancy*
Ever pregnant during follow-up 97.7 0.99 (0.98 to 0.99); 0.01 0.99 (0.98 to 1.00); 0.12
Never pregnant during follow-up 98.7 Reference Reference
% of Visit Months With ‡80% Adherence
OR of ‡80% Adherence
(95% CI); P
Adjusted OR of ‡80%
Adherence (95% CI); P
Clinic-based pill count adherence, limited to women
experiencing pregnancy†
Periconception period 94.4 0.88 (0.50 to 1.55); 0.65 1.01 (0.50 to 2.04); 0.98
Visits before periconception period 97.1 Reference Reference
% Visits With Detectable
Tenofovir
HR of Detectable Tenofovir
(95% CI); P
Adjusted HR of Detectable Tenofovir
(95% CI); P
Tenofovir detection in plasma, women
assigned to active PrEP (TDF or FTC/
TDF)‡
Visits when pregnancy discovered (cases) 71.4 0.59 (0.34 to 1.03); 0.06 0.81 (0.43 to 1.52); 0.51
Visits from nonpregnant women (cohort) 80.5 Reference Reference
*Population: all women. Analysis: log-binomial regression with generalized estimating equations; adjusted analysis controls for age, unprotected sex, sex with an additional
partner, use of an effective contraceptive method, and time in the study.
†Population: women experiencing pregnancy. Analysis: conditional logistic regression; adjusted analysis controls for unprotected sex, sex with an additional partner, use of an
effective contraceptive method, and time in the study.
‡Population: women in the active PrEP arms, including women who experienced pregnancy and a random selection of women without pregnancy. Analysis: case-cohort design to
up-weight data from women in the random sample and use a Cox proportional hazards regression; adjusted analysis controls for age, unprotected sex, sex with an additional partner, use
of an effective contraceptive method, and time in the study.
HR, hazard ratio; OR, odds ratio; RR, relative risk.
FIGURE 1. Adherence relative to pregnancy
among 267 women with pregnancies. Percentage
of women taking at least 80% of pills prescribed
(by clinic-based pill count) is graphed on the y
axis. Number of months before pregnancy is on
the x axis, month 0 is the month where pregnancy
was first detected. The percentage of women with
high adherence did not differ by month.
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Qualitative data suggest that higher medication adherence in
the Partners PrEP Study may have been partially because of
partner involvement.37 In addition, although neither trial re-
ported prospective pregnancy intention data, qualitative inter-
views with 36 couples experiencing pregnancy while enrolled
in the Partners PrEP Study suggested that most intended to
become pregnant or were pleased when they discovered they
were pregnant.38 Thus, it is possible that most of the preg-
nancies in the Partners PrEP Study were intended or planned.
HIV-1 prevention studies enrolling women from sub-
Saharan Africa have reported pregnancy incidence ranging
from 3.95/100 person-years in the CAPRISA 004 trial of
tenofovir vaginal gel in South Africa36 to 52/100 person-
years in a phase 2 trial of oral tenofovir in West Africa.19
High pregnancy incidence in studies providing access to and
counseling about contraception highlights the importance of
HIV-1 prevention for women who may want to conceive
with an infected or high-risk partner.39,40 Factors associated
with incident pregnancy in this study included younger age,
unprotected sex, having an outside partner, and not being on
effective contraception. These associations are intuitive and
consistent with previous reports of pregnancy predictors
among women enrolled in HIV-1 prevention trials.16–18,41
Interestingly, our data did not show an association with
partner CD4 cell count or ART use, suggesting that women
were not making decisions to conceive based on markers of
HIV-1 transmission risk from their partners. Our results do
not point to a specific group to target in safer conception
interventions but highlight that sexually active women of
reproductive age who are not on contraception may benefit
from routine discussions of fertility goals and counseling for
the best HIV-1 risk-reduction strategies given her goals.
Women who enroll in a clinical trial without plans for preg-
nancy merit ongoing counseling sensitive to the fact that her
goals may change over time.40
Limitations to this study include interpreting pregnancy
incidence without prospective data around fertility intention.
Second, studying adherence to an intervention with unknown
efficacy (at the time of the study) with blinded randomization
to placebo makes both the measure of adherence and the
significance of the findings an imperfect reflection of what
delivery of effective PrEP might find. Although this analysis
focuses on the periconception period, women having children
within serodiscordant partnerships remain at risk after
conception. Couples who achieve pregnancy are at particular
risk for transmitting and acquiring HIV with associated risks
of perinatal transmission.42–44 Risk-reduction interventions,
including PrEP, should continue to be evaluated for women
during pregnancy and postpartum periods.
In conclusion, these data show that women at risk for
HIV-1 acquisition within stable, mutually disclosed, HIV-1–
serodiscordant partnerships, with understanding of that
risk,45 and with ready access to condoms, contraception,
and counseling still have a high pregnancy rate. In addition,
they remained highly adherent to PrEP, both overall and
around the time of conception. Now that FTC/TDF is
approved and recommended for use as oral PrEP46–48 and
there is enthusiasm for PrEP as a safer conception strat-
egy,10–12 implementation and demonstration projects should
include women with pregnancy and/or plans for pregnancy
to understand the risks, the benefits, and challenges to bio-
medical prevention in this high priority group.
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